Overview
The speaker discusses Merck (MRK), a leading pharmaceutical company whose stock has dropped significantly due to concerns over an upcoming patent expiration for its top-selling drug. They argue that the current low valuation and strong dividend present a compelling long-term investment opportunity.
Recent Stock Performance and Concerns
- Merck's stock has fallen nearly 40% from its peak, underperforming the broader market.
- The decline is primarily due to concerns over the 2028 patent expiration of Keytruda, the world's top-selling cancer drug.
- Investors fear generic competition will sharply reduce Keytruda's revenues.
- Additional challenges include a 55% drop in Gardasil sales in China.
Market Sentiment and Cyclicality
- Investors often shy away from pharma stocks during downturns, despite previously wishing they had bought at lower prices.
- The sector typically follows cycles: growth via blockbusters, decline post-patent, then recovery with new drug development or acquisitions.
- Historical stock charts show Merck has rebounded after previous major dips.
Valuation and Dividend Analysis
- Merck now trades below its price from over 20 years ago, making its valuation (PE/PEG ratios) ~50% cheaper than the sector median.
- The dividend yield is around 4%, near historical highs for Merck, supported by a low 40% payout ratio.
- Merck has paid and grown its dividend consistently for 35 years, doubling it in the past decade with the potential to double again in the next ten years.
Business Turnaround and Growth Strategy
- Merck is developing a subcutaneous Keytruda formulation, extending its patent protection into the 2030s.
- The company has spent over $32 billion on recent acquisitions (Prometheus, Acceleron, Verona) to strengthen its drug pipeline.
- Merck's pipeline includes 50+ programs in phase 2 and 30+ in phase 3 trials, having tripled its late-phase projects since 2021.
- New drugs are contributing to growth: Wellrec up 30%, Lynparza up 15%, new launches like Capvaxie and Winrevair generating strong early sales.
- The animal health segment is growing by double digits, exceeding $1.5B per quarter.
Operational and Strategic Initiatives
- Merck is executing a $3 billion annual cost optimization plan, focusing on reducing administrative and real estate expenses and reinvesting savings into R&D.
- The company is investing in U.S. manufacturing to mitigate tariff and supply chain risks.
Speaker’s Perspective and Closing
- The speaker believes Merck’s management has a robust plan to navigate current risks and that the stock’s current price offers significant value.
- They encourage viewers to share their opinions and conduct their own research before making investment decisions.
Questions / Follow-Ups
- Do you agree Merck is a buy at these levels, or is the sector too risky given economic and regulatory conditions?
- Are there other biotech or pharma stocks you prefer in the current market?